Chinese english Japanese Germany Korea
ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Proteases >Proteasome inhibitors >CEP-18770

CEP-18770

CEP-18770 Structure
CAS No.
847499-27-8
Chemical Name:
CEP-18770
Synonyms
CS-252;CT 47098;CEP-18770;CIP 18770;NPH 007098;Delanzomib;Delanzomib, >=98%;CEP-18770 (DelanzoMib);DelanzoMib (CEP-18770);DelanzoMib, Free Base, >99%
CBNumber:
CB42570998
Molecular Formula:
C21H28BN3O5
Molecular Weight:
413.28
MOL File:
847499-27-8.mol
Modify Date:
2023/5/18 11:31:10
Request For Quotation

CEP-18770 Properties

Melting point 178-190°C (dec.)
Density 1.207
storage temp. Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
form Solid
pka 9.67±0.43(Predicted)
color White to Off-White
Stability Hygroscopic

SAFETY

Risk and Safety Statements

HS Code  29333990

CEP-18770 Chemical Properties,Uses,Production

Description

Delanzomib is an orally bioavailable inhibitor of chymotrypsin-like proteasome activity (IC50 = 3.8 nM in isolated human erythrocytes) that only marginally inhibits tryptic and peptidyl glutamyl proteasome activity. Delanzomib pre-treatment (20 nM) in vitro inhibits IκBα degradation, NF-κB activation, and the expression of NF-κB-regulated genes, including IκBα, XIAP, TNF-α, IL-1β, ICAM-1, and VEGF. Delanzomib induces apoptosis in multiple myeloma cell lines and inhibits proliferation in a panel of human hematologic and solid tumor cell lines (IC50s = 5.6-34.2 nM). It reduces tumor weight in an RPMI 8226 human multiple myeloma mouse xenograft model when administered intravenously at doses ranging from 1.5-4 mg/kg twice daily and leads to complete tumor regression at a chronic oral dose of 13 mg/kg. Delanzomib reduces the serum level of circulating cytokines, prevents renal tissue damage, and increases lifespan in a mouse model of fatal lupus nephritis.

Uses

Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.

CEP-18770 Preparation Products And Raw materials

Raw materials

Preparation Products

CEP-18770 Suppliers

Global( 119)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Alpha Biopharmaceuticals Co., Ltd +86-15542445688 China 888 58 Inquiry
Hangzhou FandaChem Co.,Ltd. 008657128800458; +8615858145714 China 9337 55 Inquiry
career henan chemical co +86-0371-86658258 +8613203830695 China 29826 58 Inquiry
SIMAGCHEM CORP +86-13806087780 China 17367 58 Inquiry
WinWin Chemical CO., Limited +86-0086-577-64498589 +86-15355981851 China 14279 58 Inquiry
AFINE CHEMICALS LIMITED +86-0571-85134551 China 15395 58 Inquiry
Baoji Guokang Bio-Technology Co., Ltd. 0917-3909592 13892490616 China 9322 58 Inquiry
Zhejiang J&C Biological Technology Co.,Limited +1-2135480471 +1-2135480471 China 10522 58 Inquiry
Nextpeptide Inc +86-0571-81612335 +8613336028439 China 19915 58 Inquiry
Guangzhou TongYi biochemistry technology Co.,LTD +8613073028829 China 2996 58 Inquiry
Supplier Advantage
Alpha Biopharmaceuticals Co., Ltd 58
Hangzhou FandaChem Co.,Ltd. 55
career henan chemical co 58
SIMAGCHEM CORP 58
WinWin Chemical CO., Limited 58
AFINE CHEMICALS LIMITED 58
Baoji Guokang Bio-Technology Co., Ltd. 58
Zhejiang J&C Biological Technology Co.,Limited 58
Nextpeptide Inc 58
Guangzhou TongYi biochemistry technology Co.,LTD 58

CEP-18770 Spectrum

CEP-18770(847499-27-8)1HNMR

847499-27-8(CEP-18770)Related Search:

CPI-455 Maritoclax GDC-0623 IMR-1 CHIR 99021 trihydrochloride
LJI308 2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide AZ191 HTH-01-015 GDC-0879
4-iodo-3-nitrobenzamide VBY-825 Bortezomib MLN9708 MK-2206 2HCl
(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Oprozomib Carfilzomib
chevron_left

1of4

chevron_right
CEP-18770 [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid CIP 18770 CT 47098 Delanzomib NPH 007098 CEP-18770 (DelanzoMib) DelanzoMib, Free Base, >99% ((R)-1-((2S,3R)-3-Hydroxy-2-(6-phenylpicolinaMido)butanaMido)-3-Methylbutyl)boronic acid (R)-1-((2S,3R)-3-hydroxy-2-(2-phenylpicolinamido)butanamido)-3-methylbutan-2-ylboronic acid Delanzomib [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid Delanzomib, >=98% DelanzoMib (CEP-18770) Boronic acid, B-[(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]aMino]butyl]aMino]-3-Methylbutyl]- (1R)-1-[(2S,3R)-3-hydroxy-2-[(6-phenylpyridin-2-yl)formamido]butanamido]-3-methylbutyl]boronic acid CS-252 CEP-18770;CEP 18770;CEP18770 ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid 847499-27-8 C21H28BN3O5 Inhibitor Inhibitors